ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag policy nih

The Price Tag of Scientific Fraud
Kerry Grens | Aug 15, 2014 | 2 min read
Each paper retracted because of research misconduct costs taxpayers roughly $400,000, according to a report.
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Genome Investigator Craig Venter Reflects On Turbulent Past And Future Ambitions
Karen Young Kreeger | Jul 23, 1995 | 8 min read
And Future Ambitions Editor's Note: For the past four years, former National Institutes of Health researcher J. Craig Venter has been a major figure in the turbulent debates and scientific discoveries surrounding the study of genes and genomes. Events heated up in 1991, when NIH attempted to patent gene fragments, which were isolated using Venter's expressed sequence tag (EST)/complementary DNA (cDNA) approach for discovering human genes (M.A. Adams et al., Science, 252:1651-6, 1991). NIH's mo
Bush Budget Would Reduce Number Of New NIH Grants
Jeffrey Mervis | Mar 1, 1992 | 6 min read
Sidebar: Wrong Number, Please Try Again The president's request for 1993 specifies more science support overall but dims hopes for some individual researchers WASHINGTON--On the surface, the 1993 budget that President Bush submitted to Congress January 29 should look very familiar to researchers: A lot more for the National Science Foundation, a little more for the National Institutes of Health, and large increases to pay for the continuing construction of the superconducting supercollider an
Congress Assails NIH Spending Practices; Report Presses For Reforms, Restraints
Jeffrey Mervis | Sep 2, 1990 | 7 min read
A House panel, demanding changes in the way grants are managed, accuses scientists of overstating the crisis in research funding WASHINGTON--In a report that has left National Institutes of Health officials "a little shell-shocked," a House committee has laid out an unprecedentedly specific set of spending guidelines in an effort to fix what it sees as a longstanding problem in the way NIH has handled its rapidly growing budget. In blunt language, the House report says its members are tired o
HHS Secretary Sullivan To Determine If NIH Gene Patent Quest Is Over
Scott Veggeberg | Oct 25, 1992 | 6 min read
The decision on whether the National Institutes of Health should continue its quest for patents on partial human cDNA sequences now rests with Health and Human Services secretary Louis Sullivan. In September, NIH director Bernadine Healy revealed that the agency had received an initial rejection from the United States Patent and Trademark Office (PTO) for the approximately 2,700 partial gene sequences generated by former NIH researcher Craig Venter and others. Then, on October 5, an HHS spok
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Those We Lost in 2019
Ashley Yeager | Dec 30, 2019 | 6 min read
The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.

Run a Search

ADVERTISEMENT